A new phase III study confirms that the breast cancer drug nanoparticle albumin-bound paclitaxel (Abraxane®, Celgene) in combination with gemcitabine (Gemzar®, Eli Lilly and Company), the current standard of for advanced pancreatic cancer, demonstrated highly statistically significant and clinically meaningful results across primary and key secondary endpoints and patient…

Final Phase III data from clinical trial with Abraxane® (paclitaxel albumin-bound particles for injectable suspension developed by Celgene Biopharmaceuticals) in combination with carboplatin in patients with advanced non-small cell lung cancer (NSCLC)shows significantly improved overall response rate for patients receiving the drug combination.



The…